An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY 59-8862 [ortataxel] in Patients With Taxane-Resistant Metastatic Breast Cancer.

Trial Profile

An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY 59-8862 [ortataxel] in Patients With Taxane-Resistant Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2009

At a glance

  • Drugs Ortataxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 26 May 2009 Actual end date (Feb 2004) added as reported by ClinicalTrials.gov.
    • 19 May 2008 Results reported at ASCO 2008.
    • 19 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top